(Q37929744)

25 August 2017

1 reference

title

Emerging GLP-1 receptor agonists (English)

1 reference

25 August 2017

Asger Lund

1

0 references

Tina Vilsbøll

series ordinal

3

object named as

Tina Vilsbøll

1 reference

25 August 2017

Filip K Knop

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

9 September 2011

1 reference

Expert Opinion on Emerging Drugs

25 August 2017

published in

1 reference

25 August 2017

volume

16

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

607-618

1 reference

The Physiology of Glucagon-like Peptide 1

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Mechanisms of action of glucagon-like peptide 1 in the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Global healthcare expenditure on diabetes for 2010 and 2030.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Diabesity: an overview of a rising epidemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Insulin treatment and the problem of weight gain in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Therapy: What evidence should guide the use of thiazolidinediones?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

GLP-1 for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Association of pancreatitis with glucagon-like peptide-1 agonist use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Lixisenatide for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Abnormal connexin expression underlies delayed wound healing in diabetic skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.616493

10.1517/14728214.2011.616493

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference